Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies.
D000038:Abscess / Q000188:drug therapy; D000818:Animals; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000627:therapeutic use*; D000917:Antibody Formation; D005620:Freund's Adjuvant; D006460:Hemolysin Proteins / Q000494:pharmacology; D007114:Immunization; D005779:Immunodiffusion; D007668:Kidney / Q000032:analysis; D007740:L Forms; D008248:Lysostaphin / Q000627:therapeutic use; D051379:Mice; D010068:Oxacillin / Q000032:analysis / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D006460:Hemolysin Proteins; D005620:Freund's Adjuvant; D008248:Lysostaphin; D010400:Penicillin G; D010068:Oxacillin